Active pharmaceutical ingredient watch. (Markets: Life Sciences).(Brief Article)

Chemical Market Reporter, August, 2002

ABBOTT LABORATORIES received formal Food and Drug Administration (FDA) approval for its $500 million synthetic thyroid hormone replacement therapy Synthroid (levothyroxine), launched in the US in 1958. Abbott filed its new drug application for Synthroid. in 2001, in lieu of the 1997 FDA decision that orally administered levothyroxine sodium products are new drugs. JP Morgan analyst Michael Weinstein says the approval removes earnings risk for the second half of 2002, meaningfully, and concerns over Abbott's relationship with the FDA.

AMGEN INC. suffered a setback last week when an UK court of appeals ruled in favor of Transkaryotic Therapies Inc. (TTK) and Aventis Pharma in a patent infringement suit involving Amgen Inc. and Kirin-Amgen Inc. The court...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.